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Background: Resistance in Plasmodium falciparum to commonly used anti-malarial drugs, especially chloroquine, is
being increasingly documented in India. By 2007, the first-line treatment for uncomplicated malaria has been
revised to recommend artemisinin-based combination therapy (ACT) for all confirmed P. falciparum cases.
Objective: The objective of this study was to compare the efficacy, safety and tolerability between
dihydroartemisinin-piperaquine (DP) and artesunate plus mefloquine (A +M) drug combinations in the treatment of
uncomplicated P. falciparum malaria in India.
Methods: Between 2006 and 2007, 150 patients with acute uncomplicated P. falciparum malaria were enrolled,
randomized to DP (101) or A +M (49) and followed up for 63 days as part of an open-label, non-inferiority,
randomized, phase III multicenter trial in Asia.
Results: The heterogeneity analysis showed no statistically significant difference between India and the other
countries involved in the phase III study, for both the PCR-corrected and uncorrected cure rates. As shown at the
whole study level, both forms of ACT were highly efficacious in India. In fact, in the per protocol population, the
63-day cure rates were 100% for A +M and 98.8% for DP. The DP combination exerted a significant post-treatment
prophylactic effect, and compared with A+M a significant reduction in the incidence of new infections for DP was
observed (respectively 17.1% versus 7.5% of patients experienced new infection within follow up). Parasite and fever
clearance was rapid in both treatment arms (median time to parasite clearance of one day for both groups). Both
DP and A+M were well tolerated, with the majority of adverse events of mild or moderate severity. The
frequencies of individual adverse events were generally similar between treatments, although the incidence of post
treatment adverse events was slightly higher in patients who received A+M with respect to those treated with DP.
Conclusion: DP is a new ACT displaying high efficacy and safety in the treatment of uncomplicated P. falciparum
malaria and could potentially be considered for the first-line treatment of uncomplicated falciparum malaria in
India.
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Malaria continues to be a major public health chal-
lenge in South East Asia, where 30% of the global
population is estimated to be at risk of malaria. India
alone contributes about 70% of reported cases [1].
More than two-third of the Indian population lives in
endemic areas where, overall, two million cases and
1,000 deaths attributable to malaria are reported annu-
ally [2]. There are regional variations in the prevalence
and transmission of the disease due to the presence of
different parasite species (mainly Plasmodium falcip-
arum and Plasmodium vivax), mosquito vectors, eco-
logical conditions, and socio-economic factors. The
Annual Parasite Incidence (API), an indicator of the
disease incidence, is reportedly less than two in most
parts of India. However, endemic regions with an API
greater than five are spread in the states of Rajasthan,
Gujarat, Karnataka, Goa, Southern Madhya Pradesh,
Chhattisgarh, Jharkhand, Orissa and the North-Eastern
states [3].
Resistance of P. falciparum to the commonly used
anti-malarial drugs, especially chloroquine, has been
progressively reported in India [4]. Assam was the first
Indian state to report cases of chloroquine-resistant mal-
aria, as early as 1973. In the following decades, chloro-
quine resistance has been documented throughout the
Indian subcontinent. More than 80% of the therapeutic
efficacy studies conducted from 2001–2007 indicate fail-
ure to chloroquine beyond cut-off level of 10% [5]. As a
consequence, the drug policy has been revised and arte-
misinin combination therapy (ACT) was introduced by
the National Vector Borne Disease Control Programme
as the first-line treatment of falciparum malaria in 117
districts, which represented more than 90% of the
reported P. falciparum cases [6]. By 2010, artesunate
plus sulphadoxine/pyrimethamine (AS + SP) was adopted
as the first-line treatment for confirmed cases of uncom-
plicated P. falciparum malaria. However, more investiga-
tions are needed for new fixed-dose combinations to
facilitate the National Programme in adopting the most
effective, easy to administer, feasible, safe and cost-
effective strategy.
Combination of artesunate and mefloquine (A+M)
has been used widely for many years in South-East Asian
countries, such as Thailand and Cambodia, and remains
highly effective for uncomplicated P. falciparum malaria.
Under the WHO system of efficacy assessment, more
than 95% of patients remain free of malaria 28 days after
A +M treatment [7]. However, the neuropsychiatric
effects of mefloquine are often problematic. No co-
formulations are commercially available, but in some
countries (i.e. Cambodia) it is available a blister pack
containing separate tablets of each constituent drug to
be administered over three days.Dihydroartemisinin-piperaquine (DP) is a potential al-
ternative; it is a fixed-dose formulation to be taken once
a day over a full treatment course of three days. In the
last decade, several clinical trials evaluating the DP com-
bination for the treatment of uncomplicated P. falcip-
arum and P. vivax malaria have been conducted in
Asian countries. The overall 28-day cure rates (Kaplan-
Meier estimates) for the DP treatment consistently
exceeded 97% in China, Myanmar, Cambodia, Laos,
Thailand and Vietnam [8].
Recently, a DP formulation produced under Good
Manufacturing Practices (GMP) has been developed by
Sigma-Tau (Rome, Italy), in collaboration with Medicines
for Malaria Venture (MMV). During years 2005–2007, a
phase III multicenter study comparing this novel formu-
lation with artesunate plus mefloquine for the treatment
of acute uncomplicated P. falciparum malaria was car-
ried out in India and two other Asian countries (Laos
and Thailand) [9]. In the present report, more detailed
results obtained by the Indian centres are reported and
the possible role of the DP combination in controlling
and eliminating malaria in India is discussed.
Methods
Study sites, patients, clinical procedures, and laboratory
analysis
Three Indian centres (Figure 1) including 150 patients,
were part of the Phase III multicentre study [9] and are
considered in this paper: Down Town Hospital, Guwa-
hati (State of Assam); Goa Medical College and Hospital
(State of Goa); and Wenlock District Government Hos-
pital, Mangalore (State of Karnataka). The sample size
calculation was only performed for the whole multicen-
ter study.
The Indian study was conducted over one malaria sea-
son, with patients screened from November 2006 to Feb-
ruary 2007. The selected centres are situated in areas of
perennial transmission (Assam), perennial transmission
with a seasonal peak from June to September (Goa), and
transmission active in post-monsoon months (Karna-
taka). Chloroquine (CQ) resistance was present at all
study sites, with site records showing 28-day treatment
failure rates of 32% in Assam (in 2002), 54% in Goa (in
2007) and 67% in Mangalore City (in 2005). ACT repre-
sents the standard treatment in Goa and Mangalore
(specifically artesunate plus sulphadoxine/pyrimeth-
amine) and Assam. For this reason, the study protocol
was amended in April 2006, requiring the prohibition of
chloroquine during the study.
Patient inclusion and exclusion criteria have been
reported elsewhere [9]. Briefly, males and females aged
from 18 to 65 years with fever or history of fever (≥37.5°C)
and microscopically confirmed P. falciparum mono- or




Figure 1 Study centres and malaria incidence. Malaria endemic areas in India (source: http://whoindia.org/LinkFiles/Malaria_Country_Profile-
Malaria.pdf). API, annual parasite incidence.
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tions were followed in India that required all recruited
patients to be aged 18 years and over. Key exclusion criteria
were: severe malaria, treatment with mefloquine in the
60 days prior to screening, treatment with DP in the three
months prior to screening and >4% parasitized red blood
cells. Pregnant or lactating women were not eligible for the
study.
At presentation, venous blood samples were taken for
parasite count, haematology, biochemistry, and 3 blood
spots were collected onto 3MM filter paper (Whatman,
Maidstone, United Kingdom) for genotyping by poly-
merase chain reaction (PCR) in the event of reappear-
ance of P. falciparum during follow-up [10]. Urine was
collected for urinalysis and β-HCG pregnancy test (for
the women of child bearing age). A 12-lead electrocar-
diogram (ECG) (CarTouch, Cardionics SA, Belgium)
was obtained.
If the study inclusion criteria were met, the patients
were randomly assigned to receive either A) A+M: arte-
sunate (Artesunate, 100 oblong Lactab; Mepha, Aesch-
Basel Switzerland), 4 mg/kg/day for 3 days (Days 0–2)
plus mefloquine (Mephaquin, Lactab; Mepha, Aesch-Basel Switzerland) 15 mg base/kg on day 1 and 10 mg
base/kg on day 2, or B) DP: Dihydroartemisinin-
piperaquine (Sigma-Tau, Rome, Italy) 2.1/16.8 mg/kg in
a single daily dose for 3 days. Each tablet contained
40 mg of DHA and 320 mg of piperaquine. The Food
and Drug Department, Ministry of Health, India
approved the use of both A+M and DP in this trial.
The treatment choice was kept in a sealed opaque en-
velope, which was opened only after the decision to re-
cruit had been made. An unequal randomization, 2:1
(DP:A +M), was used to provide more precise estimates
of DP cure rates, as well as to provide more patients for
the safety database of DP. Axillary temperature was
measured every six hours. Study drug administration
was observed directly by the study physician. Study med-
ications were given as tablets or fractions of tablets,
according to body weight, given orally with a glass of
water. Patients were observed for one hour to ensure
that the medications were not vomited or regurgitated.
Patients were observed daily until parasites cleared,
then weekly for 63 days from the start of treatment, or
at other times if he/she felt unwell. At each visit finger
prick blood was taken for a malaria smear and
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papers from those patients with reappearance of asexual
parasitaemia for parasite genotyping [11]. Twelve-lead
ECGs were obtained on days 2 and 7 and on days 28
and 63 if the results were abnormal on day 7; ECGs were
also obtained on the day of P. falciparum recurrence.
Venous blood samples were taken for haematologic and
biochemical analysis on days 28 and 63 if the results
were abnormal on day 28 and were also performed on
the day of P. falciparum recurrence.
Patients with treatment failure were withdrawn from
the study, treated, and followed up as per local practice.
They did not have to undergo efficacy evaluation there-
after. Patients requiring rescue therapy were treated with
artesunate 2 mg/kg/day orally for seven days plus doxy-
cycline if there was no contraindication. Any patient
diagnosed with severe malaria or danger signs during
follow-up was referred for treatment with parenteral
artesunate and supportive measures at the local facility
or hospital. Those patients who received additional
courses of therapy were also followed-up for 63 days.
Potential adverse events were recorded.
Written informed consent was obtained from all parti-
cipants. Ethical clearance for the study was granted by
the following ethics committees: Institutional Ethics
Committee, National Institute of Malaria Research
(ICMR), Delhi, India; Goa Medical College and Hospitals
Local Ethics Committee, Goa, India; Institutional Ethics
Committee, Kasturba Medical College, Mangalore, India.
The trial registration number is ISRCTN 81306618. The
trial was monitored by MDS Pharma Services.
Parasite counts in thick and thin films stained with
Giemsa were obtained daily until parasite clearance and
then weekly from day 7 up to day 63 [9]. At screening,
parasite density was calculated by counting the number
of asexual parasites per 500 leukocytes in the thick blood
film, based on an assumed white cell count of 8000
cells/μL. After randomization, parasite density was cal-
culated as: (number of parasites counted x 8000)/(num-
ber of leukocytes counted). For samples with higher
level of parasitemia (>3 parasites/1000 red blood cells),
parasite density was calculated from the thin film as:
(number of P. falciparum trophozoites per 1000 red
blood cells x haematocrit x 125.6). Polymerase chain re-
action amplification was performed on paired samples
for parasite genotyping to distinguish between reinfec-
tion and recrudescence. To this aim, three spots of
blood were collected onto 3MM filter paper (Whatman,
UK). Filter papers were dried and individually stored in
a plastic bag containing silica gel. All filter papers were
subsequently transferred to the Institute of Tropical
Medicine (Antwerp, Belgium) where centralized geno-
typing was conducted; deoxyribonucleic acid was puri-
fied as described elsewhere [9]. Three polymorphicgenetic markers, MSP1, MSP2 and GluRP were used to
distinguish recrudescence from new infections [12]. Re-
crudescence was defined as at least one identical allele
for each of the three markers in the pre-treatment and
post-treatment samples. New infections were diagnosed
when all alleles for at least one of the markers differed
between the two samples.
Outcomes of the study
The primary endpoint of the study was the PCR-
corrected cure rate on day 63, based on the adequate
clinical and parasitological response (ACPR), which was
defined as the absence of parasitaemia irrespective of the
patient’s body temperature, with the patient not meeting
any of the criteria of early treatment failure or late clin-
ical or parasitological failure [13]. This definition of cure
rate, which was agreed with the Data Monitoring and
the Clinical Development Committees, was based on a
pre-defined procedure that expanded the WHO defini-
tions with a set of specific rules [9].
Secondary endpoints included PCR-corrected adequate
clinical and parasitological response on days 28 and 42,
PCR-uncorrected adequate clinical and parasitological
response (PCR-uncorrected), proportion of patients with
treatment failure, proportion of aparasitaemic patients,
proportion of afebrile patients, number of new infec-
tions, gametocyte carriage and the safety profile of the
two treatments including adverse events and electrocar-
diograph parameters.
Statistical analysis
The Breslow-Day heterogeneity test or a logistic regres-
sion model [14] were used to verify homogeneity of
results (PCR-corrected and uncorrected cure rates at
day 63) across India and the other countries involved in
the phase III study [9]. A p-value lower than 0.1 was
considered statistically significant for interpreting the
heterogeneity tests.
The two most extreme populations, i.e. Intention to
Treat (ITT) and Per Protocol (PP) populations, were
presented in this work, in line with the presentation of
the whole study results [9]. The ITT population was
defined as all randomized patients who took at least one
dose of study treatment. In this population, all patients
lost to follow-up and all the withdrawals for reasons that
could be interpreted as treatment-related (i.e. vomiting
of study drugs or withdrawal of informed consent), as
well as patients for whom the PCR was missing at two
consecutive scheduled visits, patients who had experi-
enced AEs resembling the recurrence of malaria or had
taken drugs with a known or suspected antimalarial ac-
tion, were evaluated as failures after being reviewed at
the Data Review Meeting. The PP population was
defined as all randomized patients who were eligible
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and exclusion criteria, received at least 80% of the study
medication, underwent the day 63 assessment, took no
other anti-malarial drugs (excluding rescue therapies)
and, in the presence of asexual parasite stages on thick
or thin blood smears, had an evaluable PCR test.
Patients who missed visits from day 1 to day 3 were
excluded from the PP population. Patients with missing
parasitaemia at two consecutive scheduled visits were
considered as failures if occurred before day 4, otherwise
they were excluded from the PP population.
The analysis of the PCR-corrected and uncorrected
cure rates at day 63, 42 and 28 was based on simple pro-
portions and 95% (two-sided) confidence intervals (CIs)
were computed on the difference between the treatment
proportions. Survival analysis techniques were applied
for analysing time to parasite clearance and estimating
the rate of new infections and true treatment failure, as
established by the WHO [13]. The latter analysis, based
on the standard definitions of early/late clinical and
parasitological failure, consisted in computing the true
treatment failure (TTF) as the sum of the early and late
(either LPF or LCF) treatment failures occurring until
day 13 (recrudescence by default) and the late treatment
failures from day 14 onwards classified as recrudescence
by PCR analysis.154 screened m
150 randomiz
Guwahati: 68 patie
Goa: 28 patients 
Mangalore: 54 pat
Day 3-28 
 9 Lost to follow-up; 1 AE 
Day 29-42  
4 Lost to follow-up  
Day 43-63  
2 Lost to follow-up  
85 patients completed the study  
ITT population: 101  
PP population: 80  
TRIAL PROFILE 
101 
Randomized to DP 
Figure 2 Trial profile.In the survival analysis performed for new infections
(ITT population), lost to follow-up, informative withdra-
wals, recrudescences, patients with missing PCR and all
the successes were censored. In the survival analysis per-
formed for true treatment failures (PP population),
patients withdrawing the study, with a new infection,
with missing PCR and all the successes were censored.
Rates of person-fever-days and person-gametocyte-
weeks were calculated as the number of weeks in which
fever was present or blood slides were positive for game-
tocytes, respectively, divided by the number of follow-up
weeks and expressed per 1,000 person-weeks.
The ITT population was used for all safety assess-
ments. Adverse events were coded using the MedDRA
dictionary (MedDRA V8.1). Proportions of patients ex-
periencing at least one adverse event were compared be-
tween treatments using the Pearson Chi square test.
Results
Trial profile and baseline characteristics
A total of 154 Indian patients were screened, with 101
patients randomized to the DP arm and 49 patients ran-
domized to the A+M arm (Figure 2). Three centres with
distinct background in terms of parasite transmission,
resistance and seasonality were selected: Guwahati in the
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(A+M) patients were enrolled; Goa, characterized by
perennial transmission with a seasonal peak in June-
September (CQ treatment failure rate ~50%), where 19
and (DP) and 9 (A+M) patients were enrolled; Manga-
lore in the Karnataka state, a seasonal transmission area
during post-monsoon months (CQ treatment failure rate
~70%), where 36 and (DP) and 18 (A+M) patients were
enrolled.
At enrolment, the DP and A+M groups had similar
demographic and clinical characteristics except that the
geometric mean parasitaemia was higher in the DP
group compared to A+M arm (Table 1). All patients
were febrile at the time of enrollment with the exception
of two subjects in the DP arm who were afebrile at ad-
mission but had a history of fever prior to admission. All





Male : female 17: 5 19: 0
Age (years)
Mean 29.1 31.2 25.9
SD 10.9 10.2 5.5
Weight (kg)
Mean 46.7 48.6 54.3
SD 7.8 7.9 8.8
Race (Asian)
% 100 100 100
Presence of fever
N 46 22 17
% 100 100 89
Temperature (°C)
Mean 37.9 37.9 38.9
SD 0.32 0.28 0.92
Parasitaemia (μ/L)
Geometric mean 5337.7 5915.1 7547.7
Hb (g/L)
Mean 98.4 91.1 124.2
SD 25.1 21.0 22.5
Populations
Safety/ITT N 46 22 19
% 100 100 100
Per Protocol N 42 22 19
% 91 100 100
DP= dihydroartemisinin-piperaquine; A +M= artesunate-mefloquine; SD= standard
37.5 °C; Hb =Haemoglobin.the local Authority regulations. Out of the 150 rando-
mized patients, 126 (84%) completed the study until day
63; 23 patients (15 patients in the DP arm; 8 patients in
the A+M arm) were lost to follow-up and one patient
in the DP arm discontinued the study after the first drug
administration because of adverse events. The propor-
tion of patients lost to follow-up was about 16% in both
the two treatment groups. However, the majority of the
patients which have been lost during follow up in both
DP (13 out of 15 patients; 2 of them at day 7 visit, 3 at
day 14, 3 at day 21, 1 at day 28, 2 at day 35 and 2 at day
42) and A+M (7 out of 8 patients; 2 of them at day 7
visit, 2 at day 14, 1 at day 28 and 2 at day 35) arms were
enrolled at the Mangalore center.
Twenty-nine patients (21 patients in the DP arm and 8
in the A+M arm) were excluded from the PP popula-
tion because lost to follow-up before or at Day 63 (seeMangalore TOTAL
A+M DP A+M DP A+M
(N=9) (N=36) (N=18) (N=101) (N=49)
8 : 1 32 : 4 17 : 1 78 : 23 42 : 7
26.1 28.5 27.7 28.3 29.0
6.8 9.6 7.8 9.6 8.9
51.0 52.9 50.2 50.4 49.6
3.3 6.6 5.5 8.2 6.4
100 100 100 100 100
9 36 18 99 49
100 100 100 100 100
38.6 38.9 38.8 38.4 38.4
0.48 0.41 0.48 0.67 0.57
6650.2 6265.1 3279.3 6032.0 4866.3
113.7 105.7 116.2 105.8 105
19.3 21.9 23.5 25.1 24.5
9 36 18 101 49
100 100 100 100 100
8 19 11 80 41
89 53 61 79 84
deviation; fever was considered present if temperature was greater or equal to
Table 2 Analysis of the cure rates at day 63 by site and
overall (ITT and PP populations)
PCR-corrected Uncorrected
DP A+M DP A+M
N (%) N (%) N (%) N (%)
95% CI 95% CI 95% CI 95% CI
ITT Population
Heterogeneity test p=0.398a p=0.800a
Guwahati 44 (95.7) 22 (100) 44 (95.7) 22 (100)
(DP=46, A+M=22) 89.76; 100 n.a. 89.76; 100 n.a.
Goa 19 (100) 8 (88.9) 19 (100) 7 (77.8)
(DP=19, A+M=9) n.a. 68.4; 100 n.a. 50.6; 100
Mangalore 18 (50.0) 11 (61.1) 12 (33.3) 5 (27.8)
(DP=36, A+M=18) 33.7; 66.3 38.6; 83.6 17.9; 48.7 7.1; 48.5
Total 81 (80.2) 41 (83.7) 75 (74.3) 34 (69.4)
(DP=101, A+M=49) 72.4; 88.0 73.3; 94.0 65.7; 82.8 56.5; 82.3
95% CI for DP - A+M −16.4; 9.5 −10.6; 20.3
PP population
Heterogeneity test p=0.978b p=0.574a
Guwahati 42 (100) 22 (100) 42 (100) 22 (100)
(DP=42, A+M=22) n.a. n.a. n.a. n.a.
Goa 19 (100) 8 (100) 19 (100) 7 (87.5)
(DP=19, A+M=8) n.a. n.a. n.a. 64.6; 100
Mangalore 18 (94.7) 11 (100) 12 (63.2) 5 (45.5)
(DP=19, A+M=11) 84.7; 100 n.a. 41.5; 84.9 16.0; 74.9
Total 79 (98.8) 41 (100) 73 (91.3) 34 (82.9)
(DP=80, A+M=41) 96.3; 100 n.a. 85.1; 97.4 71.4; 94.4
95% CI for DP - A+M −3.7; 1.2 −4.8; 21.4
DP, dihydroartemisinin-piperaquine; A+M, artesunate-mefloquine; n.a., not
assessable.
aBreslow-Day; bLogistic Regression.
Gargano et al. Malaria Journal 2012, 11:233 Page 7 of 12
http://www.malariajournal.com/content/11/1/233above) or had major protocol violations. Major protocol
violations occurred only in the DP arm: PCR missing or
indeterminate or not done before or at day 63 (3
patients); subjects not taking at least 80% of the study
drug medication (1 patient); subjects having haemoglo-
bin value below the lower limit (< 5 g/dL) at day 0 or
missing at day 0 and day 7 (2 patients) and no availabil-
ity of the Day 63 assessment (2 patients).
Clinical and parasitological outcomes
One early treatment failure (ETF) was observed in the
DP arm due to an adverse event (grand mal convulsion)
occurring after the first drug administration. Due to this
event, the study drug was discontinued and his malaria
was successfully treated with primaquine plus quinine.
No late treatment failure (LTF) was observed in both
ITT and PP populations for the A+M study group at
the end of follow up (day 63). For the DP arm, two late
clinical failures were observed in the PP population due
to recurrent parasitaemia occurring in two patients at
day 39 and day 45, respectively.
In the analysis of the PCR-corrected cure rate at day
63, DP was found to be similar to A+M (Table 2 and
Figure 3). For the ITT population, cure rates were
80.2% (DP) and 83.7% (A+M) (95% CI for DP minus
A+M: -16.4% to 9.5%); for the PP population, cure rates
were 98.8% (DP) and 100% (A+M) (95% CI: -3.7% to
1.2%). These results were similar to those obtained at the
overall phase III study level: slightly lower for ITT and
quite the same for PP (at the whole study level, the com-
parison DP vs A+M was 87.9% vs 86.6% in ITT, and
98.7% vs 97.0% in PP). The heterogeneity analysis showed
no statistically significant difference between India and the
other considered countries in both the PCR-corrected and
uncorrected cure rates at day 63.
The 95% CIs are quite wider as compared to those
obtained in the phase III study as result of the small size
of the Indian sample. When looking at the PCR-
uncorrected cure rate at day 63, results were in favour of
DP. In the ITT population the cure rates were 74.3%
(DP) and 69.4% (A+M) with a difference of 4.9% (95%
CI for DP-A+M: -10.6% to 20.3%) while in the PP popu-
lations the cure rates were 91.3% (DP) and 82.9% (A+M)
with a difference of 8.4% (95% CI for DP-A+M: -4.8% to
21.4%). With respect to the overall phase III findings, the
Indian results were better in terms of absolute values (at
the whole study level, the comparison DP vs A+M was
67.3% vs 59.6% in ITT, and 75.5% vs 66.4% in PP).
As for the other time-points (day 42 and day 28)
analogous findings were observed in all study popula-
tions (data not shown).
The treatment difference on uncorrrected cure rates
was mainly due to new infections (Figure 4), which are
higher in the A+M arm, as shown by the Kaplan-Meierestimates of the proportion of patients with new infec-
tions at day 63: 7-8% (DP) and 17% (A+M) in both ITT
and PP populations. These results are similar to those
obtained at the overall study level when looking at the
comparison between treatments, but lower in terms of
absolute values (at the whole study level, Kaplan-Meier
estimates were 22.7% and 23.4% for DP, and 30.3% and
31.4% for A+M, in the ITT and PP populations, respect-
ively. The new infections (6 patients in the DP arm and
7 patients in the A+M arm) were mainly observed in
Mangalore (12 patients; 6 for DP and 6 for A+M) and
mostly occurred after 42 days of follow up (11 patients
from day 45, one at day 16 and one at day 21); only one
new infection occurred in a patient who was assigned to
the A+M arm at the Goa centre. Notably, 12 out of 13
new infections were due to a Plasmodium species differ-
ent from P. falciparum.
Parasite clearance was rapid in both treatment groups
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Figure 3 Treatment outcome.








Day 0 99/101 (98.0) 49/49 (100.0) 1.000
Day 1 45/101 (44.6) 21/49 (42.9) 0.844
Day 2 30/100 (30.0) 14/49 (28.6) 0.857
Day 3 23/100 (23.0) 10/49 (20.4) 0.720
Day 7 13/98 (13.3) 7/46 (15.2) 0.752
Overall (day 0 - day 7) 99/101 (98.0) 49/49 (100.0) 1.000
Person-fever-days3 260/695 (374.1) 125/334 (374.3) 0.994
Parasitaemia
Day 0 101/101 (100) 49/49 (100)
Day 1 37/101 (36.6) 15/49 (30.6)
Day 2 7/101 (6.9) 4/49 (8.2)
Day 3 0 0
DP= dihydroartemisinin-piperaquine; A +M= artesunate-mefloquine.
1Calculated, at a given time (i.e. Day 0, Day 1 etc.), as number of patients with
fever (≥37.5°C) divided by the number of patients having reached that time;
2Pearson Chi-square or Fisher’s exact test, as appropriate;
3Calculated as number of days in which temperature was greater or equal to
37.5 during the first study week divided by the total number of follow up days
in the first week and expressed per 1,000 person-days.
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study; 93.1% of DP-treated patients and 91.8% of A+M-
treated patients were aparasitaemic on day 2 and 100%
of patients in each arm were aparasitaemic on day 7
(ITT population). Kaplan-Meier estimates of median
time to parasite clearance were 1 day for each treatment
group in all the analysis populations.Figure 4 Rates of new infections by treatment group at day 63. Lost t
withdrawals are censored at the withdrawal time, patients imputed as recr
recrudescence, patients with recrudescence detected by PCR are censored
done PCR at failure are censored at day of failure, patients classified as succ
of patients at risk of new infection is reported at weekly visits by treatment
DP, dihydroartemisinin-piperaquine.Fever clearance was also fast in both arms (Table 3)
and proportions of afebrile patients were comparable to
those observed for aparasitaemic patients, with superim-
posable profiles. Fever prevalence, calculated as the
number of days in which temperature was greater oro follow-up are censored at the drop-out time, informative
udescence (day of failure< day 4) are censored at the time of
at day of failure, patients with not interpretable or missing or not
ess are censored at the time of day 63 assessment. The number
group under the Kaplan-Meier curves. A +M, artesunate-mefloquine;
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total number of follow-up days in the first week, was
similar for DP- and A+M-treated patients; 260/695
(374.1) versus 125/334 (374.3) (p = 0.994) respectively.
The gametocyte carriage was assessed at weekly visits,
from day 7 onwards. The time to clearance of gameto-
cytes is reported in Table 4. In the A+M group, there
were no patients with gametocytes at day 7. As for the
DP group, most of the patients (93%) cleared their
gametocytaemia by day 7. At day 14, five patients in the
DP arm (5%) still had gametocytes in their peripheral
blood and all of them cleared gametocytaemia by day 28.
The overall gametocyte prevalence throughout the study
(from day 7 to day 63) in the DP group, estimated as
person-gametocyte-weeks, was 22.1 weeks/1,000 patients
in the ITT population and 13.7 weeks/1000 patients in
the PP population.
Blood haemoglobin (Hb) was evaluated weekly. In the
ITT population, 5 (5%) patients in DP and 4 (8%)
patients in A+M presented with an Hb level< 70 g/L.
Three of these patients (two in the DP group and one in
the A+M group) worsened at day 7 and a SAE was
communicated by the investigator (see below); all the
other patients stabilized or improved their anaemic sta-
tus by the following visit. There was no apparent differ-
ence between treatment groups. In the ITT population,Table 4 Prevalence and incidence of gametocytes during
the study (ITT population)
DP n/N (%) A+M n/N (%)
Gametocyte prevalence1
Day 7 7/98 (7.1) 0/46 (0.0)
Day 14 5/94 (5.3) 0/44 (0.0)
Day 28 0/89 (0.0) 0/42 (0.0)
Day 42 0/85 (0.0) 0/41 (0.0)
Day 63 0/81 (0.0) 0/41 (0.0)
Overall (day 7 - day 63) 9/98 (9.2) 0/46 (0.0)
Gametocyte incidence2
Day 7 7/98 (7.14) 0/46 (0.0)
Day 14 2/94 (2.13) 0/44 (0.0)
Day 28 0/89 (0.0) 0/42 (0.0)
Day 42 0/85 (0.0) 0/41 (0.0)
Day 63 0/81 (0.0) 0/41 (0.0)
Person-gametocyte-weeks3 18/814 (22.1) 0/391 (0.0)
DP= dihydroartemisinin-piperaquine; A +M= artesunate-mefloquine.
1Calculated, at a given time, as number of patients with gametocytes at that
time divided by the number of patients having reached that time;
2Calculated, at a given time interval, as number of new patients with
gametocytes in that interval divided by the number of patients having
reached the end of that interval;
3Calculated as number of weeks in which blood slides were positive for
gametocytes during the whole study (up to a maximum duration of 70 days)
divided by the number of all follow-up weeks and expressed per 1,000
person-weeks.the mean Hb fell from 105.8 g/l (DP) and 104.5 g/L
(A+M) on day 0 to 103.2 g/l (DP) and 100.6 g/l (A +M)
on day 7, before increasing steadily thereafter (Table 5).
Such changes in Hb are expected in acute malaria.
Adverse events
Both DP and A+M were well tolerated with the major-
ity of adverse events of mild or moderate severity, and
consistent with symptoms attributable to malaria. The
frequencies of individual adverse events were generally
similar between treatments, although the incidence of
post treatment adverse events (AEs) was slightly higher
in patients who received A+M with respect to those
treated with DP (Table 6). In particular, the highest dif-
ferences in favour of DP were observed for asthenia
(DP:10%; A +M: 18%; p = 0.144) and decreasing number
of red blood cells (DP: 11%; A +M: 20%; p = 0.115); a re-
sult in the opposite direction was for the event “Eosino-
phils count increased” (DP: 13%; A +M: 4%; p = 0.092),
but none of these AEs was judged by the investigator as
serious.
Six serious adverse events (SAE) were observed during
the study until day 63 of follow up: five in the DP arm
and one in the A+M group. All patients recovered com-
pleted by the end of the study.
In the DP group, five SAE occurred in five patients.
One patient (24 years old male, weight 54 kg) developed
malaria of moderate severity on day 39 which was con-
sidered not to be related to the study drug by the inves-
tigator. His malaria was treated with oral quinineTable 5 Haemoglobin changes from day 0 to day 14 (ITT
Population)
DP A+M
Day 0 n 101 49
mean (SD) 105.8 (25.1) 104.5 (24.5)
min/max 45/177 50/158
Day 7 n 98 46
mean (SD) 103.2 (23.2) 100.6 (26.2)
min/max 40/170 45/170
Day 14 n 94 43
mean (SD) 108.4 (21.7) 103.4 (24.0)
min/max 50/170 45/145
Day 14 – Day 0 n 94 43
mean (SD) 2.7 (15.3) −0.1 (16.0)
min/max −47/41 −45/51
Haemoglobin is expressed in g/L.
Difference between treatments on the changes from baseline to day 7:
p = 0.76.
Difference between treatments on the changes from baseline to day 14:
p = 0.34.
DP= dihydroartemisinin-piperaquine; A +M= artesunate-mefloquine;
SD= standard deviation.
Table 6 Proportions of adverse events by treatment
group
Event (MedDRA Preferred Term)1 DP n (%) A+M n (%)
At least one AE 60 (59.4%) 33 (67.4%)
Anaemia 6 (5.9%) 4 (8.2%)
Asthenia 10 (9.9%) 9 (18.4%)
Pyrexia 18 (17.8%) 10 (20.4%)
Malaria2 5 (5.0%) 7 (14.3%)
Eosinophil count increased 13 (12.9%) 2 (4.1%)
Haematocrit decreased 11 (10.9%) 5 (10.2%)
Haemoglobin decreased 13 (12.9%) 7 (14.3%)
Red blood cell count decreased 11 (10.9%) 10 (20.4%)
At least one SAE 5 (5.0%) 1 (2.0%)
At least one drug-related SAE 4 (4.0%) 1 (2.0%)
AE, adverse event; SAE serious adverse event; DP, dihydroartemisinin-
piperaquine; A +M, artesunate-mefloquine.
1Shown are Adverse Events with a frequency> 5%.
2Reporting of malaria as an adverse event was not complete in this study.
Some study centres chose not to report malaria as it was known that to enter
the study all patients had to have Plasmodium falciparum infection.
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One subject (male, aged 20 years, weight 61 kg) had
Wolff-Parkinson-White (WPW) syndrome diagnosed on
day 2. The investigator thought this was possibly related
to DP. However, since WPW is a congenital cardiac con-
duction anomaly it cannot be caused by DP. One patient
(male, aged 38 years, weight 57 kg), with no history of
convulsions, suffered a grand mal convulsion three
hours after the first DP dose. The event was treated with
i.v. phenytoin 900 mg/day and diazepam 10 mg/day. DP
was discontinued and his malaria was treated with
primaquine 45 mg/day orally and quinine 600 mg/day
orally. He recovered completely. In the investigator’s
opinion the convulsion was possibly related to DP. Two
patients developed worsening anaemia that was consid-
ered unlikely to be related to DP by the investigators. In
particular, the first patient (male, aged 35 years, weight
50 kg) was anaemic at enrolment (Hb 45 g/dL). The an-
aemia worsened by day 7 (Hb 40 g/dL) which was con-
sidered a life-threatening SAE. Ferric ammonium citrate
320 mg/day was started on day 7 and continued up to
study completion. The second patient (female, aged
25 years, weight 39 kg) was anaemic at enrolment (Hb
50 g/dL). The anaemia worsened by day 7 (Hb 40 g/dL)
which was considered a life-threatening SAE by the in-
vestigator. Ferric ammonium citrate 320 mg/day was
started on day 7 and continued until day 35.
In the A+M group, one SAE (severe anaemia) oc-
curred in one patient. The subject (female, 40 years,
weight 42 kg) was anaemic at enrolment (Hb 50 g/dL)
and became severely anaemic by day 8 (Hb 45 g/dL).
She was treated with ferric ammonium citrate 320 mg/
day and recovered fully. The investigator thought itunlikely that the anaemia was related to the investiga-
tional drug.
No deaths were observed during the study.
Discussion
Malaria is one of major public health problems in India.
Malaria in India contributes significantly to the world
malaria burden. The National Vector Borne Disease
Control Program of India reported around 1.6 million
cases and 1100 malaria deaths in 2009 [15]. Some
experts argue that this is an underestimation and that
the actual number of malaria cases per year is likely be-
tween 9 and 50 times greater, with an approximate 13-
fold underestimation of malaria-related mortality. The
exact numbers remain the subject of debate and require
further study [15,16]. Undebated is that the problem of
malaria in India is substantial.
In 2005–2007 a phase III, multi country trial of oral
DP versus A+M was conducted in 1150 Asian patients
with acute uncomplicated P. falciparum malaria [9]. This
study included three Indian sites, the data of which are
extracted and analysed in this work. The heterogeneity
analysis was performed to verify homogeneity of results
across India and the other countries involved in this
phase III study. It was shown that the overall results of
the phase III study also applied to India. However, it
must be noted that the Indian sample size is about 13%
of the overall Asian phase III study, meaning that the In-
dian results are less precise than those obtained at the
whole study level, determining cure rates to be estimated
within wide confidence limits, even if the rate of success
is similar to that reported using DP in other regions of
Asia [9].
One of the strengths of this study is that it was done in
settings of different transmission and had a prolonged
follow-up period of 63 days not to miss late reinfections
and to reflect the terminal half-lives of the drugs [17,18].
One of the study limitations is that it was not blinded so
that an influence on the evaluation of the tolerability can-
not be excluded. In terms of robustness of the trial, this
weakness was mitigated with a blinded randomization
procedure.
In 2010, artesunate plus sulphadoxine-pyrimethamine
combination became the first-line treatment for con-
firmed P. falciparum malaria in India. These products
are only available as co-blistered formulations and are
only prescribed for adults above 15 years of age [6]. As
DP is a fixed dose combination could potentially yield
better compliance, and less risk of diverting the co-
blistered artesunate into monotherapy. Artemisinin
monotherapy use was widespread across India, and this
is thought to be one of the key drivers to the possible
creation of resistance to artemisinins, the backbone of
worldwide treatment of malaria. In addition, with the
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sulphadoxine-pyrimethamine (SP) alone and more re-
cently in combination with artesunate is used first line
treatment for malaria. Due to continuous drug pressure,
the P. falciparum parasite is now exhibiting resistance to
anti-folates, though for the time being most parasites are
sensitive to the drug. The reported resistance strains
have been shown to be so because of mutations in can-
didate genes dihydrofolate reductase (dhfr) and dihy-
dropteroate synthetase (dhps) [19]. The use of a highly
effective safe fixed dose ACT might help reduce the
drug pressure on SP.
One of the limitations of this study is the lack of chil-
dren below 18 years of age. The burden in children in
India remains [20] significant. In other geographic areas
DP has been shown to be useful in both children and
adults. The use of the drug in Indian children needs to
be studied. This is the first study of the use of DP in the
Indian population, with 101 patients receiving the com-
bination. It provides information on DP in communities
in Assam, Goa and Mangalore. These Indian communi-
ties had notable levels of chloroquine resistance, with
historical site records showing treatment failure rates for
chloroquine treatment ranging from 32% to 67% (based
on a 28 days of follow-up). Based on the structural simi-
larities of chloroquine and piperaquine, there was the
theoretical potential for cross-resistance to chloroquine
which might have resulted in a low response to DP.
However, the DP combination appeared to be unaffected
by any potential cross-resistance, and performed uni-
formly well in all Indian settings.
The DP combination exerted a significant post-
treatment prophylactic effect in this study. Significant
reductions in the incidence of new infections for DP
compared with A+M were seen. Higher uncorrected
cure rates were observed in the DP arm than with
A+M, as the uncorrected cure rate endpoint includes
new infections as well as recurrence of infection. This
effect is thought to be caused by residual levels of drug
remaining in the body because of the longer half-life of
piperaquine. The post-treatment prophylaxis was better
for DP reflecting the differential terminal half-life of
piperaquine and mefloquine (22–25 days versus 14 days,
respectively). The post-treatment prophylactic effect is
of particular importance in regions with a high risk of
new infection. This can reduce the risk of anaemia and
allow patients more time for haematological recovery
between infections.
Mefloquine has been linked with adverse events of
gastrointestinal and central nervous system origin [21].
In this study, the frequency of reporting of nausea,
vomiting and dizziness was 2–3 fold higher in the A+M
arm than the DP arm. Vomiting soon after dosing is an
important determinant of treatment efficacy as attainingand maintaining effective systemic levels of anti-malarial
drugs is essential to disease outcome. For patients to ac-
cess DP via public sector healthcare systems, this fixed
dose combination requires regulatory approval.
In conclusion, the fixed dose dihydroartemisinin-
piperaquine in this study emerged as a highly efficacious
treatment for P. falciparum malaria in India. The com-
bination of DP provided some protection against new
infections post treatment. DP can play an important role
in controlling and eliminating malaria in India, possibly
in the context of multiple first-line treatments of un-
complicated falciparum malaria, which will reduce drug
pressure on existing combinations.
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